Recent Finacing
Recent Raise
Bionure develops SGK2-activating small molecules; lead BN201 promotes neuronal survival and remyelination by driving OPC differentiation, targeting NOA and NMO with a Phase 1 safety, pharmacokinetics trial underway.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Bionure.
